Resultado de búsqueda
S2.1-26 RCTs and systematic reviews with meta-analyses demonstrated greater reduction of ASCVD risk with team-based care than with usual care in patients with hypertension, diabetes, and hyperlipidemia.
- View EPUB
¾ •V_ eɼÆyi@µþË— ú Ÿ– Œ ^9žºà3O{…6 ë& *7 6! ä̤/.³éR\!êìW2E...
- Low-Calorie Sweetened Beverages and Cardiometabolic Health
American Heart Association’s Published Statements and...
- Seafood Long-Chain N-3 Polyunsaturated Fatty Acids and Cardiovascular Disease
In 2 large prospective cohorts, higher concentrations of...
- Sedentary Behavior and Cardiovascular Morbidity and Mortality
On the basis of objective measurement from accelerometers,...
- Heart Disease and Stroke Statistics—2018 Update
Table 2-6. Summary of Evidence-Based Population Approaches...
- Table 2
Introduction. Suboptimal diet is the leading risk factor for...
- Cardiovascular Quality and Outcomes
2.74 (1.10–6.83), n=2: ... The Reynolds risk score is sex...
- Electronic Cigarettes
E-Cigarettes or ENDS. The first concept of an electric...
- View EPUB
In patients with clinical ASCVD, reduce low-density lipoprotein cholesterol (LDL-C) with high-intensity statin therapy or maximally tolerated statin therapy. The more LDL-C is -sequent risk reduction. Use a maximally tolerated statin to lower LDL-C levels by ≥50%. 3. In very high-risk ASCVD, use a LDL-C thresh-old of 70 mg/dL (1.8 mmol/L) to ...
primary prevention of ASCVD because of lack of net benefit. 9.Statin therapy is first-line treatment for primary prevention of ASCVD in patients with elevated low-density lipoprotein cholesterol levels (≥190 mg/dL), those with diabetes mellitus, who are 40 to 75 years of age, and those determined to be at
29 de abr. de 2019 · Elevated lipoprotein(a): A relative indication for its measurement is family history of premature ASCVD. A lipoprotein(a) ≥50 mg/dL or ≥125 nmol/L constitutes a risk-enhancing factor, especially at higher levels of lipoprotein(a).
7 de mar. de 2019 · The focus is primary prevention in adults to reduce the risk of ASCVD (acute coronary syndromes, myocardial infarction, stable or unstable angina, arterial revascularization, stroke/transient ischemic attack, peripheral arterial disease), as well as heart failure and atrial fibrillation.
The 2018 guideline narrows the use of the atherosclerotic cardiovascular disease (ASCVD) risk calculator, provides more guidance on the use of risk-enhancing factors in making statin therapy...
31 de jul. de 2021 · LDL levels have been causally associated with the risk of atherosclerotic cardiovascular disease (ASCVD) through absolute magnitude and cumulative duration of LDL-C exposure . There is no current evidence for an established protective role for HDL against atherosclerosis .
